Related Experiment Video
Updated: Jul 19, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
South Africa's "rollout" of highly active antiretroviral therapy: a critical assessment
1AIDS and Society Research Unit, University of Cape Town, Private Bag Rondebosch 7701, Cape Town, South Africa. nicoli.nattrass@gmail.com
The number of people on highly active antiretroviral therapy (HAART) in South Africa has risen from < 2000 in October 2003, to almost 200,000 by the end of 2005. Yet South Africa's performance in terms of HAART coverage is poor both in comparison with other countries and the targets set by the government's own Operational Plan. The public-sector HAART "rollout" has been uneven across South Africa's nine provinces and the role of external assistance from NGOs and funding agencies such as the Global Fund and PEPFAR has been substantial. The National Treasury seems to have allocated sufficient funding to the Department of Health for a larger HAART rollout, but the Health Minister has not mobilized it accordingly. Failure to invest sufficiently in human resources--especially nurses--is likely to constrain the growth of HAART coverage.
The number of people on highly active antiretroviral therapy (HAART) in South Africa has risen from < 2000 in October 2003, to almost 200,000 by the end of 2005. Yet South Africa's performance in terms of HAART coverage is poor both in comparison with other countries and the targets set by the government's own Operational Plan. The public-sector HAART "rollout" has been uneven across South Africa's nine provinces and the role of external assistance from NGOs and funding agencies such as the Global Fund and PEPFAR has been substantial. The National Treasury seems to have allocated sufficient funding to the Department of Health for a larger HAART rollout, but the Health Minister has not mobilized it accordingly. Failure to invest sufficiently in human resources--especially nurses--is likely to constrain the growth of HAART coverage.
Related Concept Videos
Retrovirus Life Cycles
Retroviruses
Therapeutic Drug Monitoring: Affecting Factors
Antiviral Nucleoside Inhibitors
Subviral Agents
Sexually Transmitted Infections

